Drug Discovery Stories

From Bench to Bedside

Bin Yu, Peng Zhan

• Publisher: Elsevier
• Year: 2024
• Topic: Business
• eBook ISBN:
  9780443239335
• Subtopic: Pharmaceutical, Biotechnology & Healthcare Industry
• Index: Business

Drug Discovery Stories: From Bench to Bedside presents a collection of cases on the development of highly successful pharmaceuticals. It delves into the realm of drug discovery, exploring the structural biology and biological functions of the sought-after targets. The book covers the identification of promising compounds, their transformation from hits to leads through meticulous optimization, and the elucidation of how key compounds interact with the target (in essence, providing invaluable insights for drug design). Additionally, it covers essential information such as the pivotal biological and PK data of lead compounds, any noteworthy clinical results, and a comprehensive overview of other candidate compounds.The field of drug discovery and development has experienced rapid evolution, with numerous new drugs receiving approval each year. While several books have been published on this subject, there is a pressing need for a new book series that accurately reflects the current advancements in drug discovery. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology. - Analyzes the drug discovery stories of different blockbuster drugs - Includes the newly approved drugs - Covers key aspects related to the drug development of the drugs

Table of contents

• Cover
• Title page
• Table of Contents
• Copyright
• Dedication
• Contents
• List of contributors
• About the editors
• Foreword 1
• Foreword 2
• List of Illustrations
• List of Tables
• Chapter 1 : Artificial intelligence in early stages of structure-based drug discovery
• Chapter 2 : Target-based vs phenotypic drug discovery: opportunities and challenges with evidence-based application
• Chapter 3 : Hit discovery from DNA-encoded chemical library
• Chapter 4 : Discovery of lead compounds from pseudo-natural macrocycles enabled by modular biomimetic strategy
• Chapter 5 : Macrocyclization strategy in kinase drug discovery
• Chapter 6 : Cobalt-catalyzed C–H functionalization for the synthesis of chiral heterocyclic molecules
• Chapter 7 : Advancing proteolysis targeting chimeras toward clinical drug developments
• Chapter 8 : A future battle, small-molecule drugs for cancer stem cell targeted therapy
• Chapter 9 : Stem cell therapies for combating emerging and reemerging viral infections
• Chapter 10 : Targeting autophagy with pharmacological small molecules to treat human diseases
• Chapter 11 : Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?
• Chapter 12 : Selenium and small molecules: a symbiotic partnership
• Chapter 13 : Novel combinations of CD33-targeted immunotherapies
• Chapter 14 : Novel payloads of antibody-drug conjugates
• Chapter 15 : Antibody−drug conjugates: a new generation of cancer vaccines
• Chapter 16 : mRNA vaccines: the next frontier in disease prevention
• Chapter 17 : Unravelling the drying techniques of protein biopharmaceuticals
• Chapter 18 : Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatment of multidrug-resistant HIV infections
• Chapter 19 : Nirmatrelvir, SIM0417, and RAY1216: potent and selective SARS-CoV-2 main protease inhibitors for the potential treatment of COVID-19
• Chapter 20 : Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
• Chapter 21 : Darolutamide: an androgen receptor antagonist for the treatment of prostate cancer
• Chapter 22 : Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer
• Chapter 23 : Zanubrutinib: a breakthrough in cancer therapy targeting Bruton’s tyrosine kinase, originating from China, and benefiting the global community
• Chapter 24 : Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia
• Chapter 25 : Ziftomenib (KO-539): a potent and selective Menin inhibitor for the treatment of recurrent or refractory acute myeloid leukemia
• Chapter 26 : Pulrodemstat (CC-90011): a highly potent, selective, and reversible lysine-specific demethylase 1 (LSD1) inhibitor
• Chapter 27 : Mavacamten, a first-in-class cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy
• Chapter 28 : Verquvo, a first-in-class soluble guanylate cyclase stimulator for the treatment of heart failure
• Chapter 29 : Tafamidis: a transthyretin stabilizer for rare cardiac amyloidosis
• Chapter 30 : Oliceridine (TRV130): a biased agonist of the μ opioid receptor as a novel analgesic
• Chapter 31 : Sotyktu (Deucravacitinib): the first tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of psoriasis
• Chapter 32 : Bexagliflozin: a sodium-glucose co-transporter-2 inhibitor as anti-diabetic drug derived from phlorizin
• Chapter 33 : Antidiabetic drugs−targeted PPARγ: from full agonists to selective modulators
• Chapter 34 : Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis
• Chapter 35 : Lecanemab (Leqembi): an amyloid beta monoclonal antibody approved for the treatment of Alzheimer’s disease
• Chapter 36 : Pembrolizumab: a breakthrough in cancer immunotherapy
• Index
• A